Koers Laboratorio Reig Jofre SA BME
Aandelen
ES0165359011
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- EUR | - |
10/05 | Laboratorio Reig Jofre, S.A. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024 | CI |
13/03 | Transcript : Laboratorio Reig Jofre, S.A., 2023 Earnings Call, Mar 13, 2024 |
Omzet 2024 * | 349 mln. 376 mln. | Omzet 2025 * | 379 mln. 409 mln. | Marktkapitalisatie | 241 mln. 260 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 11 mln. 11,88 mln. | Nettowinst (verlies) 2025 * | 14 mln. 15,12 mln. | EV/omzet 2024 * | 0,81 x |
Nettoschuld 2024 * | 39,5 mln. 42,66 mln. | Nettoschuld 2025 * | 33,3 mln. 35,96 mln. | EV/omzet 2025 * | 0,72 x |
K/w-verhouding 2024 * |
21,9
x | K/w-verhouding 2025 * |
17
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 21,21% |
Recentste transcriptie over Laboratorio Reig Jofre SA
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 56 | 01-01-06 | |
Carmen Esclapés
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-03 |
Chief Operating Officer | 52 | 01-01-03 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 56 | 01-01-06 | |
Director/Board Member | - | 31-12-14 | |
Director/Board Member | - | 31-12-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+45,82% | 765 mld. | |
-6,16% | 354 mld. | |
+19,86% | 331 mld. | |
+9,32% | 299 mld. | |
+18,45% | 248 mld. | |
-0,78% | 219 mld. | |
+11,88% | 216 mld. | |
+5,90% | 164 mld. | |
-0,73% | 162 mld. |